1-18 of 18
Ralph E. Parchment
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B138: Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response

Brian Ko, Geraldine H O'Sullivan Coyne, Abdul Rafeh Naqash, Thomas J George, David DeRemer, Larry Rubinstein, Jennifer Zlott, Deborah Wilsker, Donna Ketchum, Stephanie Runkle, Katherine V Ferry-Galow, Ralph E Parchment, Naoko Takebe, Sarah Shin, Andrea R Voth, Jiuping Ji, S. Percy Ivy, James H Doroshow, Alice P Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B138.
https://doi.org/10.1158/1535-7163.TARG-23-B138
Published: 01 December 2023
View article titled, Abstract B138: Pharmacodynamics-driven phase 2 trial of talazoparib in patients with advanced solid tumors and aberrations in genes involved in DNA damage response
Journal Articles

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

William G. Herrick, Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O'Sullivan Coyne, Andrea M. Gross, Barry C. Johnson, Alice P. Chen, Brigitte C. Widemann, James H. Doroshow, Ralph E. Parchment, Apurva K. Srivastava
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (4): 749–760.
https://doi.org/10.1158/1535-7163.MCT-20-0566
Published: 01 April 2021
View article titled, Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies
Open the PDF for Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies in another window
Includes: Supplementary data
Journal Articles

Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes

Sabrina S. Khan, Geraldine O'Sullivan, Larry Rubinstein, Shivaani Kummar, Lamin Juwara, Jennifer Zlott, Arjun Mittra, Murielle Hogu, Jerry Collins, Apurva Srivastava, Brandon Miller, Ralph E. Parchment, Christopher S. Hourigan, Steven Pavletic, James Doroshow, Alice P. Chen, Naoko Takebe
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A071.
https://doi.org/10.1158/1535-7163.TARG-19-A071
Published: 01 December 2019
View article titled, Abstract A071: Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes
Journal Articles

Abstract A050: Validation of β-catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsy specimens

Tony Navas, Robert J. Kinders, Hala Makhlouf, Scott M. Lawrence, Rodrigo Chuaqui, Krisitin Fino, Angie Dull, Katherine Ferry-Galow, Deborah Wilsker, Alice P. Chen, Shivaani Kummar, Ralph E. Parchment, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A050.
https://doi.org/10.1158/1535-7163.TARG-19-A050
Published: 01 December 2019
View article titled, Abstract A050: Validation of β-catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsy specimens
Journal Articles

Abstract B018: Restoration of p16INK4A expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes

Lihua Wang, Brandon Miller, Sonny Khin, Geraldine O’Sullivan-Coyne, Alice P. Chen, Shivaani Kummar, Naoko Takebe, Kate Ferry-Galow, Ralph E. Parchment, Larry Rubinstein, Richard Piekarz, Edward M. Newman, James H. Doroshow, Robert J. Kinders
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B018.
https://doi.org/10.1158/1535-7163.TARG-19-B018
Published: 01 December 2019
View article titled, Abstract B018: Restoration of p16<sup>INK4A</sup> expression in circulating tumor cells in patients with advanced solid tumors treated with deoxycytidine analogs and associated dynamic EMT phenotypic changes
Journal Articles

Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors

Apurva K. Srivastava, Melinda G. Hollingshead, Jeevan Prasaad Govindharajulu, Joseph M. Covey, Dane Liston, Melanie A. Simpson, James O. Peggins, Donald P. Bottaro, John J. Wright, Robert J. Kinders, James H. Doroshow, Ralph E. Parchment
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (3): 698–709.
https://doi.org/10.1158/1535-7163.MCT-17-0552
Published: 28 February 2018
View article titled, Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors
Open the PDF for Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract A002: Evidence of pazopanib-induced epithelial-mesenchymal transition (EMT) in human tumors

Tony Navas, Apurva K. Srivastava, Katherine Ferry-Galow, Hala Makhlouf, Rodrigo Chuaqui, Robert J. Kinders, Donald P. Bottaro, Alice P. Chen, Ralph E. Parchment, Shivaani Kummar, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A002.
https://doi.org/10.1158/1535-7163.TARG-17-A002
Published: 01 January 2018
View article titled, Abstract A002: Evidence of pazopanib-induced epithelial-mesenchymal transition (EMT) in human tumors
Journal Articles

Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation

William G. Herrick, Casey L. Kilpatrick, Melinda Hollingshead, James H. Doroshow, Ralph E. Parchment, Apurva K. Srivastava
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B081.
https://doi.org/10.1158/1535-7163.TARG-17-B081
Published: 01 January 2018
View article titled, Abstract B081: Elucidating the pharmacodynamics of PI3K and Ras-Raf signaling through isoform-specific multiplexed quantification of downstream effector phosphorylation
Journal Articles

Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy

Tony Navas, Robert J. Kinders, Scott M. Lawrence, Katherine Ferry-Galow, Thomas D. Pfister, Apurva K. Srivastava, Sergio Y. Alcoser, Melinda G. Hollingshead, Lindsay M. Dutko, Brad A. Gouker, Donna O. Butcher, Hala Makhlouf, Rodrigo Chuaqui, Donald P. Bottaro, Shivaani Kummar, Alice Chen, James H. Doroshow, Ralph E. Parchment
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-B18.
https://doi.org/10.1158/1535-7163.TARG-15-LB-B18
Published: 01 December 2015
View article titled, Abstract LB-B18: Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy
Journal Articles

Abstract C278: Topoisomerase 1 immunoassay provides proof of target engagement by the indenoisoquinoline class of topoisomerase 1 inhibitors in canine lymphomas.

Thomas D. Pfister, Katerine V. Ferry-Galow, Tariq Mohabbat, Robert J. Kinders, Chand Khanna, Christina Mazcko, Ralph E. Parchment, Yves Pommier, Joseph E. Tomaszewski, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C278.
https://doi.org/10.1158/1535-7163.TARG-13-C278
Published: 01 November 2013
View article titled, Abstract C278: Topoisomerase 1 immunoassay provides proof of target engagement by the indenoisoquinoline class of topoisomerase 1 inhibitors in canine lymphomas.
Journal Articles

Abstract C197: Fluorescent in situ hybridization confirmation of circulating alveolar soft part sarcoma cells (CTCs) isolated from peripheral blood specimens using ApoStream™ instrumentation.

Priya Balasubramanian, Lihua Wang, Shivaani Kummar, Melinda Hollingshead, Francis Owusu, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Robert J. Kinders
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C197.
https://doi.org/10.1158/1535-7163.TARG-13-C197
Published: 01 November 2013
View article titled, Abstract C197: Fluorescent in situ hybridization confirmation of circulating alveolar soft part sarcoma cells (CTCs) isolated from peripheral blood specimens using ApoStream™ instrumentation.
Journal Articles

Abstract A214: Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Improved performance of the Top1 immunoassay for analysis of tumor biopsies.

Ralph E. Parchment, Katherine Ferry-Galow, Jay Ji, Yiping Zhang, Thomas D. Pfister, Robert J. Kinders, Yvonne A. Evrard, Shivaani Kummar, Joseph E. Tomaszewski, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A214.
https://doi.org/10.1158/1535-7163.TARG-13-A214
Published: 01 November 2013
View article titled, Abstract A214: Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Improved performance of the Top1 immunoassay for analysis of tumor biopsies.
Journal Articles

Abstract PR11: Use of a DNA damage multiplex immunofluorescence assay to monitor pharmacodynamic markers following in vitro exposure to therapeutic agents.

Allison M. Marrero, Deborah Wilsker, Scott M. Lawrence, Thomas D. Pfister, John Hirt, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Robert J. Kinders
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): PR11.
https://doi.org/10.1158/1535-7163.TARG-13-PR11
Published: 01 November 2013
View article titled, Abstract PR11: Use of a DNA damage multiplex immunofluorescence assay to monitor pharmacodynamic markers following in vitro exposure to therapeutic agents.
Journal Articles

Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.

Jay Ji, Yiping Zhang, Robert Kinders, Christophe Redon, Stephanie Solier, Keli Agama, Yves Pommier, William Bonner, Melinda Hollingshead, Larry Rubinstein, Alice Chen, Shivaani Kummar, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A46.
https://doi.org/10.1158/1535-7163.TARG-11-A46
Published: 12 November 2011
View article titled, Abstract A46: A novel immunoassay (ELISA) for quantitative gamma-H2AX detection and pharmacodynamic monitoring of DNA damage induced by chemotherapeutic agents and PARP inhibitors.
Journal Articles

Abstract A106: Investigation of 5-fluorodeoxycytidine with tetrahydrouracil as a demethylation regimen in solid tumors.

Robert J. Kinders, Lihua Wang, Shivaani Kummar, Sonny Khin, Priya Balasubramanian, Weimin Zhu, Ralph E. Parchment, Edward Newman, Joseph E. Tomaszewski, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A106.
https://doi.org/10.1158/1535-7163.TARG-11-A106
Published: 12 November 2011
View article titled, Abstract A106: Investigation of 5-fluorodeoxycytidine with tetrahydrouracil as a demethylation regimen in solid tumors.
Journal Articles

Abstract C3: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens.

Robert J. Kinders, Sook Ryun Park, Sonny Khin, Melinda G. Hollingshead, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C3.
https://doi.org/10.1158/1535-7163.TARG-11-C3
Published: 12 November 2011
View article titled, Abstract C3: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens.
Journal Articles

Abstract C224: A novel validated quantitative pharmacodynamic topoisomerase I covalent‐complex immunoassay

Thomas D. Pfister, Sonny A. Khin, Keli Agama, Melinda Hollingshead, Dhriti Sooryakumar, Yves Pommier, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Robert J. Kinders
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C224.
https://doi.org/10.1158/1535-7163.TARG-09-C224
Published: 10 December 2009
View article titled, Abstract C224: A novel validated quantitative pharmacodynamic topoisomerase I covalent‐complex immunoassay
Journal Articles

Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

Thomas D. Pfister, William C. Reinhold, Keli Agama, Shalu Gupta, Sonny A. Khin, Robert J. Kinders, Ralph E. Parchment, Joseph E. Tomaszewski, James H. Doroshow, Yves Pommier
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1878–1884.
https://doi.org/10.1158/1535-7163.MCT-09-0016
Published: 14 July 2009
View article titled, Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
Open the PDF for Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity in another window
Includes: Supplementary data